According to a recent LinkedIn post from Axtria, the company is promoting an upcoming Ignite webinar focused on artificial intelligence in life sciences forecasting. The post cites data that 82% of pharma organizations reportedly have not applied AI to any core forecasting assumption, despite AI being a top priority for forecasting teams.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates the webinar will explore where AI can create value without requiring complete workflow overhauls and identify practical generative AI entry points for current forecasting environments. It also references the 2026 Life Sciences Forecasting Benchmarking Report as a source of insights on closing what is described as an AI forecasting adoption gap.
Featured speakers include Axtria’s forecasting head and principal Jeff Olive and AstraZeneca’s business planning and capabilities director Eric Haskel, suggesting cross‑company practitioner input. For investors, the event positioning implies Axtria is seeking to deepen its role as a thought partner and solutions provider in AI‑enabled forecasting for pharma clients.
If Axtria can translate this thought leadership into demand for its analytics and forecasting offerings, it could support revenue growth and higher‑value engagements within the life sciences vertical. More broadly, emphasis on practical AI deployment may strengthen the firm’s competitive stance in data‑driven commercial and planning solutions as pharma customers look to operationalize AI at scale.